ARTELO BIOSCIENCES INC ARTL 深 滬
等待開盤 07-18 09:30:00 美东时间
15.67
+0.490
+3.23%
華盛通- 最 高16.15
- 今 開15.50
- 成交量 8.81万股
- 最 低 14.94
- 昨 收 15.18
- 總市值 856.84万
- 52周最高 28.60
- 市盈率 靜 --
- 換手率 16.10%
- 52周最低 4.9176
- 委 比 -97.78%
- 總股本 54.68万
- 歷史最高 450.00
- 量 比 0.33
- 振 幅 7.97%
- 歷史最低 4.9176
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences announced preclinical data showing ART26.12, a novel FABP5 inhibitor, significantly alleviates osteoarthritis pain in animal models without tolerance. The drug, a non-opioid, non-steroidal analgesic, demonstrated efficacy comparable to naproxen, with sustained pain relief over four weeks. It also increased plasma levels of endocannabinoids 2-AG and OEA, correlating with reduced pain. Unlike NSAIDs, ART26.12 may offer a safer al...
07-09 11:50
Artelo Biosciences Analyst See It As An Emerging Biotech
Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its candidate for depression.
07-09 03:06
Artelo Unveils New Depression Drug Data, Shows Zoloft-Level Efficacy With Added Cognitive Benefits
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological
07-07 19:46
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
The presentation highlights ART12.11's potential as a next-gen antidepressant, demonstrating strong antidepressant-like effects and cognitive benefits over leading SSRIs. The cocrystal of CBD and TMP showed efficacy comparable to sertraline in treating stress-induced depressive symptoms, with superior cognitive restoration. Patented until 2038, ART12.11 is being discussed at the 35th Annual International Cannabinoid Research Society Symposium.
07-07 11:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants.
06-30 22:18
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences announced positive results from the first-in-human study of ART26.12, a novel FABP5 inhibitor for pain management. The Phase 1 study in 49 healthy volunteers showed excellent safety, predictable pharmacokinetics, and a wide therapeutic window. ART26.12, the first orally active, peripherally restricted FABP5 inhibitor, targets lipid signaling pathways to provide analgesic effects. With chronic pain market values projected to gro...
06-30 11:45
Artelo Biosciences Enters Into Definitive Securities Purchase Agreement For At-The-Market Private Placement For Gross Proceeds Of ~$1.425M
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological
06-26 20:05
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Artelo Biosciences, a clinical-stage pharmaceutical company, has entered into a definitive agreement for a private placement to raise approximately $1.425 million. The funds will be used to announce clinical data for its phase 1 and phase 2 studies and to purchase the digital currency SOL, with the remainder allocated for general corporate purposes.
06-26 12:00
